Surgeons delve into the pros and cons of a variety of vitreoretinal surgical viewing technologies.
How to best tap into government assistance, manage staff, carefully increase office visits and return to a more regular surgical schedule.
A look at the drug therapies that may eventually bear fruit against a disease that has resisted previous attempts at treatment.
A look at both the potential benefits—and possible drawbacks—of artificial intelligence.
These new additions to the OCT arena may help with surgical maneuvers, but new research could improve them further.
A review of the many treatments in the research pipeline for retinal diseases that have continuously resisted treatment.
Pentosan polysulfate therapy, a common treatment for interstitial cystitis, has been associated with a maculopathy.
A look at retinal surgery innovations, from visualization to instrumentation.
Surgeons with experience using a novel, prototype technology explain how it works.
OCTA has some advantages, but FA and ICG outperform it in some areas, say these physicians.